

International Collaboration on Cancer Reporting

ABN 69 601 723 960

ANNUAL REPORT 2024

CONTENTS

1. Message from the president.....	4
1.1 Four Workstreams	4
1.2 Dataset development.....	4
1.3 Translation	5
1.4 Implementation	5
1.5 Education	6
1.6 Sustainability	6
1.7 Thank you.....	7
2. ICCR's Vision and Mission	7
2.1 Vision statement	7
2.2 Mission statement	7
3. Goals and Objectives	7
3.1 Development of cancer pathology datasets.....	7
3.2 Translation of datasets into multiple languages	7
3.3 Implementation of ICCR datasets.....	8
3.4 Education	8
4. Organisational overview	8
4.1 Membership.....	9
4.2 Board of Directors	10
4.3 Council.....	10
4.4 Dataset Steering Committee	11
4.5 Dataset Authoring Committees.....	11
4.6 Structured Reporting Implementation Committee	11
4.7 Honorary Advisory Panel.....	11
5. Dataset development	11
5.1 Published datasets.....	12
5.2 International Standard Book Numbers (ISBN)	13
5.3 Datasets in progress.....	13
5.3.1 Genitourinary	13
5.3.2 Endocrine	13
5.3.3 Gastrointestinal tumours – expansion of current datasets	14
5.3.4 Neuroendocrine tumours	14
5.3.5 Skin tumours	14
5.3.6 Haematolymphoid tumours.....	14
5.4 Datasets in planning.....	14
5.5 TNM staging.....	14
5.6 Peer-reviewed publications	15
6. Translation	15
6.1 Datasets translated	15
6.2 Breast Suite	16
6.3 Ukrainian	16
6.4 Italian.....	16
6.5 German.....	16
6.6 Future translation	17
7. Implementation	18
7.1 Structured Reporting Implementation Committee (SRIC)	18
7.2 Electronic ICCR datasets	18
7.3 Terminology	18
8. Finances	19
8.1 Budget.....	19
8.2 Audited financial statement	19

8.3 Sustainability	19
8.4 Sponsorship	19
9 Appendix	20
9.1 Published datasets.....	20
9.2 Peer-reviewed publications	29

1. MESSAGE FROM THE PRESIDENT

The International Collaboration on Cancer Reporting (ICCR) has made significant progress in meeting our goals in the four strategic workstreams 2024. As in previous years our principal focus has been on the development of new datasets and on updating existing datasets to maintain currency with the World Health Organization (WHO) World Classification of Tumours 5th series. There have also been significant achievements in three other workstreams, i.e., Dataset translation, Implementation and Education, and in developing a Philanthropic Approach strategy aimed at ensuring the ICCR's sustainability as well as securing funding for expanding our translation work.

1.1 Four Workstreams

Our work

1. Reporting Standards development of cancer pathology reporting datasets	2. Translation of datasets into multiple languages	3. Implementation of ICCR datasets into electronic forms for integration into electronic health databases/ records	4. Education to increase awareness of the ICCR datasets and their use to increase patient health
---	--	--	--

1.2 Dataset development

The development of international standards for pathologists reporting cancers is the ICCR's core business and the Dataset Steering Committee (DSC) and various Dataset Authoring Committees (DAC) have had a busy and productive year. The ICCR is indebted to the Chairs and members of these committees for their invaluable work on developing and updating the datasets, each of which incorporates contemporary morphologic and molecular standards from partner organisations. These include global standard setters such as the International Agency on Cancer Research (IARC), the WHO, the Union for International Cancer Control (UICC) TNM, and the American Joint Committee on Cancer (AJCC), as well as specialty pathology societies from fields such as gynaecological, urological, breast, paediatric and head and neck pathology, among others. Synthesis of these standards and input from our expert DAC members from around the world enable the ICCR datasets serve as a bridge between the standard developers and the global pathology community.

The ICCR has 62 published datasets to date, including datasets for the top ten solid tumours worldwide. Eleven ICCR datasets have also been updated in the last 12 months to reflect the latest WHO Classification of Tumours and TNM staging, and a further 12 updates are in progress. Eight new datasets are also in development. More than 60 articles related to the ICCR datasets or work of the ICCR in peer-reviewed journals have been published.

The DSC Quality Assurance Sub-committee has a new lead, Ekkehard Hewer (handing over from Tim Helliwell) and additional members have joined. The work of this committee in ensuring that the datasets are of the highest quality and fit-for-purpose is one of the unique strengths of the dataset development process overseen by the DSC.

The ICCR has been represented at the UICC TNM Annual meeting, IC3R Annual meeting, WHO Editorial Standing Committee meetings, and at a joint session at the European Congress of Pathology.

1.3 Translation

Translation of the datasets has been identified as a key priority for the ICCR, especially with the feedback that ICCR datasets are valued globally. The ICCR website has been accessed from 187 countries to date, and in the last 12 months we have seen 45 000 active users, indicating the traction these datasets are receiving worldwide. The top 10 countries of users include the United States, India, Australia, United Kingdom, Japan, Italy, Germany, China, Brazil and France and the top 3 dataset suites being accessed are for Breast, Female Reproductive Organs and Digestive Tract cancers.

The image below was generated by Google Analytics data of the ICCR website, and illustrates the number of users, by country, who visited the ICCR website in the last 12 months.



A number of collaborations are in development with the goal to accomplish translations of ICCR datasets into German, Italian and Ukrainian.

The ICCR continues to pursue collaborations with member pathology organisations, middleware and laboratory information system (LIS) vendors to discuss further opportunities for future translations.

1.4 Implementation

Electronic implementation of the ICCR datasets is a vital step towards their integration into routine reporting practice and utilisation worldwide. The Structured Reporting Implementation Committee (SRIC), which was convened in 2021 to guide this process, has been investigating potential structured reporting tools for low and middle-income countries (LMICs) and in planning the formulation of electronic versions of the ICCR datasets for upload into Laboratory Information Systems (LIS). In the last year SRIC committee has explored the necessary requirements for transposing the PDF ICCR datasets into electronic formats, which could then be used in future within electronic health records/ databases and continued engagement with software vendors. Results from the survey to low-to-middle income countries revealed that pathologists reporting in major cities in Africa mostly have access to laboratory information systems and internet connections. Half of survey respondents use structured reporting in routine practice.

In collaboration with our partners the has worked on developing terminology to support analysis and comparison of data, quality assurance, overseeing of implementation projects, and improving cancer registry interface standards. The ICCR and SNOMED International have drafted a set of principles to lay the groundwork for a collaboration agreement for SNOMED CT reference sets for all ICCR datasets to be made available globally for free and maintained into the future. Letters of support were provided from SNOMED member countries from around the world who endorse the project.

The SNOMED-CT coding of ICCR datasets continues to progress and forms a key component of the collaboration with SNOMED International and will assist with the standardisation and interoperability of cancer reporting data worldwide. Coding for several datasets has been carefully reviewed by the SNOMED-CT Validation Standing Committee in their fortnightly meetings. This important work could not take place without the generous support of our collaborators at the University of Nebraska Medical Centre. The ICCR is also one of the Participating Organisations in the NCI's Cancer PathCHART (Cancer Pathology Coding Histology and Registration Terminology), which aims to develop a unified resource for deriving public health statistics from pathology reporting for cancer prevention programs and research.

1.5 Education

The Education workstream was initiated in 2023 and has been steadily progressing. This year, as a pilot project the ICCR collaborated with the World Continuing Education Alliance (WCEA) to conduct a webinar on the pathology of cervical cancer. The webinar targeted audiences in Sub-Saharan Africa and the content was delivered in English and French. Speakers included Dr Kay Park (gynaecological pathologist and Chair of ICCR Carcinoma of the cervix dataset), Dr Nadeem Abu-Rustum (gynaecological surgeon and president-elect of the International Gynaecologic Cancer Society), as well as panellist Professor Edwin Wiredu (gynaecological pathologist and author of the ICCR Carcinoma of the cervix dataset). More than 5,000 people were registered for the inaugural event and the live webinar was attended by 970 health professionals.

Additionally, the ICCR participated in a special European Society of Pathology (ESP)/International Agency for Research on Cancer (IARC)/ICCR joint session on tumour classification and structured reporting at the European Congress of Pathology (ECP) held in Florence. The Special joint session included presentations on classification and structured reporting implementation and the codification and secondary uses of cancer pathology data. This session was well attended and was followed by a lively panel discussion.

The ICCR will continue to seek partnerships with relevant organizations to continue the development of the Education workstream. We aim to facilitate educational events such as webinars for professional development, University and College lectures, outreach sessions and conference presentations.

1.6 Sustainability

The ICCR is grateful for the indispensable support of 18 international pathology organisation members, and the membership fees have continued to drive the maintenance and growth of the four workstreams of the ICCR. Future funding is crucial to the delivery of key projects within the four workstreams.

Additionally, the ICCR thanks Donna Meredith, the Managing Director of Keystone Corporate Positioning, who has offered her services pro bono, to develop the Philanthropic Approach strategy aiming to gain additional funding.

1.7 Thank you

On behalf of the ICCR Board and Council, I would like to express our sincere thanks and gratitude to all our members, sponsoring organisations and strategic partners for their invaluable support again this year. Their contributions and those of the numerous pathologists from our membership, who have voluntarily and enthusiastically have contributed their time and expertise, have enabled the ICCR to make significant progress in all four workstreams. We are especially thankful to the Chairs of both the Dataset Steering Committee, Sigurd Lax, and of the Structured Reporting Implementation Committee, George Birdsong, for their vital work and expert input. Finally, we are grateful to our General Manager, Rajuel Nandakumar, and Tina Selinger, who was acting General Manager during Rajuel's maternity leave, as well as all the project managers and assistants for their tireless efforts over the last year.

James Kench, President ICCR

2. ICCR's VISION AND MISSION

2.1 Vision statement

Internationally standardised, multilingual and machine-readable pathology reports documenting cancer subtype, grade, stage and other morphologic and molecular tumour parameters are necessary to improve patient care and outcomes and to advance cancer control in populations.

2.2 Mission statement

The International Collaboration on Cancer Reporting (ICCR) produces internationally standardised pathology datasets incorporating contemporary morphologic and molecular parameters which are translated into multiple languages and are available in machine readable formats. The datasets are based on strong scientific evidence and are used primarily to improve patient care. High quality data also facilitate population-level cancer control initiatives including cancer registration, epidemiology, quality research, resource planning and education.

3. GOALS AND OBJECTIVES

3.1 Development of cancer pathology datasets

Cancer patient outcomes are positively impacted by the ability of the medical team to build treatment and management options based on accurate and complete information from the patients' pathology reports. Developing complete, evidence-based cancer datasets containing essential and current reporting information for a given cancer provides the foundation for improved cancer staging and optimisation of treatment. The ICCR now has over sixty cancer datasets available for download.

3.2 Translation of datasets into multiple languages


Translating the ICCR datasets into numerous languages is essential to facilitate the implementation of standardised cancer reporting worldwide. In particular, the ICCR is focused on bridging equity access to support pathologists practicing in Low and Middle-Income Countries (LMICs) to effectively communicate complete cancer pathology results to associated clinicians, cancer registrars and other secondary users, thus ultimately benefiting cancer patients globally.

3.3 Implementation of ICCR datasets

Implementation of the ICCR datasets is crucial to their progression, integration and utilisation worldwide. This will involve investigating structured reporting tools for LMICs, developing electronic versions of the ICCR Datasets for upload into Laboratory Information Systems (LIS), development of terminology to support analysis and comparison of data, quality assurance, oversight of implementation projects, and improving cancer registry interface standards.

3.4 Education

In 2019 the International Association of Cancer Registries (IARC) endorsed the ICCR Datasets as the international standard for cancer pathology reporting. ICCR datasets have enormous educational value for pathologists, oncologists, and other related medical professionals for training and professional development, as well as providing pathologists in developing parts of the world with a benchmark and, therefore, a 'ladder' for progression and advancement in cancer reporting as their capability improves. The ICCR aims to facilitate educational events such as webinars for professional development, University and College lectures, outreach sessions, and conference presentations.




4. ORGANISATIONAL OVERVIEW

The ICCR was founded by major pathology organisations from around the world to produce internationally standardised and evidence based datasets for the pathology reporting of cancer. Its goal is to improve cancer patient outcomes worldwide and to advance international benchmarking in cancer management.

The ICCR was incorporated as a not-for-profit organisation in September 2014.

The organisational structure is as follows:



4.1 Membership

The ICCR is supported by membership and sponsorship.

The ICCR currently has three levels of membership:

- Platinum - which provides the member organisation with both Council and DSC representation. The annual subscription for a Platinum member is \$20,000 USD.
- Gold - which provides the member organisation with both Council and DSC representation. The annual subscription for a Gold member is \$10,000 USD.
- Silver - which provides the member organisation with DSC representation only. The annual subscription for a Silver member is \$5,000 USD.

Membership provides the principal amount of funding on which the ICCR depends.

As of December 2024, the ICCR has two Platinum members, which are:

- Royal College of Pathologists of Australasia (RCPA), and
- American Society of Clinical Pathology (ASCP).

These members have provided additional contributions above their membership fees and were recognised with elevation to Platinum membership at a 50% discount.

As of December 2024, ICCR has fourteen Gold members, which are:

- European Society of Pathology (ESP),
- Royal College of Pathologists United Kingdom (RCPATH),
- College of American Pathologists (CAP),
- Royal College of Physicians of Ireland, Faculty of Pathology (RCPI FoP),
- German Society of Pathology (DGP),
- Brazilian Society of Pathology (SBP),
- Hong Kong College of Pathologists (HKCPATH),
- Austrian Society of Pathology/Austrian Division of the International Academy of Pathology (ÖGPATH/IAP Austria),
- Japanese Society of Pathology (JSP),
- Italian Society of Pathological Anatomy and Cytology (SIAPEC),
- Swiss Society of Pathology (SSP),
- Belgian Society of Pathology (BSP),
- Chinese Society of Pathology (CSP), and
- Professional Association of German Pathologists (BDP).

As of December 2024, there are three Silver members, which are:

- Canadian Association of Pathologists (CAP-ACP),
- The Canadian Pathology Quality Assurance – Assurance qualité canadienne en pathologie (CPQA-AQCP), and
- Singapore General Hospital.

4.2 Board of Directors

The ICCR Board of Directors comprises of: Professor James Kench (President), Professor Kieran Sheahan (Vice President), Professor Annie Nga-Yin Cheung (Director), Associate Professor Kerry Ireland-Jenkin (Director) and Professor Peter Schirmacher (Director).

4.3 Council

The role of the ICCR Council is to expand and promote the work of the ICCR by providing strategic guidance and recommendations to the ICCR Board of Directors. Each Platinum and Gold member can appoint one representative to the Council and one observer (for succession planning purposes).

4.4 Dataset Steering Committee

The ICCR DSC has responsibility for all activities relating to the development of ICCR datasets. The DSC invites representation from all sustaining members, as well as strategic partners, including IARC, the International Association of Cancer Registries (IACR) and the European Organisation for Research and Treatment of Cancer (EORTC).

Sigurd Lax of the Austrian Society of Pathology/Austrian Division of the International Academy of Pathology holds the position of Chair of the ICCR DSC.

4.5 Dataset Authoring Committees

Dataset Authoring Committees (DACs) are convened as needed for the development of specific datasets. DAC members are recognised as honorary contributors to the ICCR for the lifetime of the datasets on which they contributed.

4.6 Structured Reporting Implementation Committee

The ICCR SRIC was convened in 2021. Its purpose is to provide guidance to the Council on matters relating to the implementation of ICCR cancer datasets, and to advance the detailed technical aspects impacting the efficient implementation of standardised cancer datasets such as electronic representation. Structured reporting options for LMICs and terminology binding. George Birdsong is the appointed Chair, SRIC.

The Board of Directors, Council, DSC, DAC and SRIC members are all volunteers that provide their expertise and time altruistically.


4.7 Honorary Advisory Panel

The Honorary Advisory Panel (HAP) was formed for the purposes of seeking strategic advice as well as retaining corporate knowledge within the organisation. The HAP meets as needed to provide ongoing guidance to the ICCR. Such guidance can include recommendations regarding sustainability, advice on strategies in relation to ICCR Workstreams, recommendations in relation to ICCR promotional activities or advice on other matters as requested by the Board from time to time.

5. DATASET DEVELOPMENT

The development of reporting standards for pathologists reporting cancers is ICCR's core business.

The ICCR dataset development follows an agreed process that is outlined in Guidelines for the Development of ICCR Datasets (<http://www.iccr-cancer.org/datasets/dataset-development>), which is reviewed and updated annually by the ICCR DSC. The process is summarised in the figure below.



The ICCR develops datasets in synchrony with the WHO Classification of Tumours updates. Dataset work commences close to the publication of the revised classification. The 5th edition of the WHO is nearing completion.

For the development of a series of datasets, the ICCR appoints a Series Champion who acts in an advisory role to the DSC to assist in the nomination of qualified candidates for the Chair and DAC roles. In addition, the Series Champion oversees the development process, supports the work of the dataset Chairs, and ensures harmonisation across the series. The responsibilities for each of the roles in a DAC are described in Roles and Responsibilities for the ICCR dataset development process (<http://www.iccr-cancer.org/datasets/dataset-development>). This document is reviewed and updated annually by the ICCR DSC.

For the development of each dataset, the DSC appoints appropriately qualified expert pathologist(s) to take on the role of Chair of the DAC. The Chair(s) are supported in the development process by a Project Manager and a representative from the ICCR DSC.

5.1 Published datasets

As of November 2024, the ICCR has published 62 datasets, with a total of 106 dataset editions published including updates. All published datasets are compliant with the latest 8th edition TNM staging, where applicable.

See Appendix 9.1 for all published ICCR datasets.

5.2 International Standard Book Numbers (ISBN)

International Standard Book Numbers (ISBN) are assigned to each ICCR dataset published.

5.3 Datasets in progress

The IARC/WHO 'blue books' are integral to all cancer datasets and as such the ICCR is committed to developing harmonised international datasets in synchrony with IARC/WHO. ICCR have a developmental schedule synchronising dataset development with IARC/WHO 'blue book' updates. Given IARC/WHO and ICCR utilise similar experts for the authorship of their documents, IARC and ICCR have agreed a process of resource allocation and timing to avoid over burdening the authorship pool.

There are 20 ICCR datasets currently in progress:

5.3.1 Genitourinary

In synchrony with the updates to the WHO Classification of Urinary and Male Genital Tumours, the ICCR has recently updated 12 existing datasets, 6 of which are still in progress as follows:

1. Renal epithelial neoplasms (update of 1st edition) (Co-Chairs: Holger Moch and Sean Williamson)
2. Renal biopsy for tumour (update of 1st edition) (Co-Chairs: Holger Moch and Sean Williamson)
3. Carcinoma of the renal pelvis and ureter - nephroureterectomy and ureterectomy specimen (update of 1st edition) (Co-Chairs: Eva Comp  rat and Toyonori Tsuzuki)
4. Carcinoma of the bladder - cystectomy, cystoprostatectomy and diverticulectomy specimen (update of 1st edition) (Co-Chairs: Eva Comp  rat and Toyonori Tsuzuki)
5. Carcinoma of the urethra - urethrectomy specimen (update of 1st edition) (Chairs: Eva Comp  rat and Toyonori Tsuzuki)
6. Urinary tract carcinoma - biopsy and transurethral resection specimen (update of 1st edition) (Co-Chairs: Eva Comp  rat and Toyonori Tsuzuki)

John Srigley, from Canada, is the appointed Series Champion.

5.3.2 Endocrine

In synchrony with the updates to the WHO Classification of Endocrine Tumours, the ICCR has commenced updates to 4 existing datasets as follows:

1. Carcinoma of the adrenal cortex (update of 1st edition) (Chair: Thomas Giordano)
2. Parathyroid carcinoma and atypical parathyroid neoplasm (update of 1st edition) (Chair: Ozgur Mete)
3. Pheochromocytoma and paraganglioma (update of 1st edition) (Chair: Ronald de Krijger)
4. Carcinoma of the thyroid (update of 1st edition) (Chair: Ronald Ghossein)

Anthony Gill, from Australia, is the appointed Series Champion.

5.3.3 Gastrointestinal tumours – expansion of current datasets

In synchrony with planned updates to the WHO Classification of Digestive System Tumours, the ICCR has commenced the development of 4 new datasets as follows:

1. Carcinoma of the appendix (Chair: Joseph Misdraji)
2. Carcinoma of the anus (Chair: Newton Wong)
3. Carcinoma of the gallbladder (Chair: Irene Esposito)
4. Liver metastases resection (Chair: Laura Rubbia-Brandt)

Iris Nagtegaal, from The Netherlands, is the appointed Series Champion.

5.3.4 Neuroendocrine tumours

In synchrony with the updates to the WHO Classification of Endocrine and Neuroendocrine Tumours and the WHO Classification of Digestive System Tumours, the ICCR has commenced the development of a new dataset for neuroendocrine tumours. The dataset will include neuroendocrine tumours of the pancreas, luminal gut and carcinoid tumours of unknown primary site. The Co-Chairs are Aurel Perren and Stefano la Rosa.

5.3.5 Skin tumours

In synchrony with the updates to the WHO Classification of Skin Tumours, the ICCR has commenced updates to 2 existing datasets as follows:

1. Invasive melanoma (update of 1st edition) (Chair: Klaus Busam)
2. Merkel cell carcinoma (update of 1st edition) (Chair: Klaus Busam)

5.3.6 Haematolymphoid tumours

In synchrony with the updates to the WHO Classification of Haematolymphoid Tumours, the ICCR has commenced the development of 3 new datasets as follows:

1. Lymphoid (Chair: German Ott)
2. Myeloid (Chair: Xueyan Chen)
3. Plasma cell myeloma (Chair: Pei Lin)

Joseph Khoury, from United States, is the appointed Series Champion.

5.4 Datasets in planning

The Eye and Orbit tumour dataset series is currently being considered for a development start in 2025.

5.5 TNM staging

8th edition

The 8th editions of the UICC and AJCC TNM Classification of Malignant Tumours were published in late 2016. Given that the UICC TNM is widely used in Europe, United Kingdom and other parts of the world, while AJCC TNM is used extensively in the North America and Australia, the ICCR was keen to be inclusive in its approach. Ostensibly these versions are harmonised, however on a more detailed review a number of differences were noted.

Having investigated the issues, the ICCR decided to use UICC TNM 8th edition in cases where there is concordance between the versions but use the AJCC TNM 8th edition in cases where the AJCC version more accurately reflects the most contemporary and scientifically validated information.

In 2020, the AJCC adopted a new approach to publication of its TNM staging system, moving from an edition-based model to a versioning approach or 'rolling updates'. In this model, the various anatomic sites will be updated individually and published separately.

At this stage the UICC has agreed to consider publishing errata to align with AJCC updates.

ICCR will continue to work with both organisations choosing the best approach for each of its datasets series.

5.6 Peer-reviewed publications

A key step in the ICCR dataset development process is the development of an accompanying article submitted to a peer-reviewed journal. To date, more than 60 ICCR dataset related manuscripts have been published.

See Appendix 9.2 for all ICCR dataset related peer-reviewed publications.

6. TRANSLATION

The ICCR considers that translation of the ICCR datasets into other languages is an essential step to advance adoption and uptake of the datasets around the world, in particular in LMIC especially as the WHO Classification of Tumours are not being translated.

Several models of translation have been discussed and various trials are underway to gather information to inform future efforts.

Currently, funding is the rate-limiting step for further translations.

6.1 Datasets translated

The following datasets translated into Spanish, French and Portuguese are available on the ICCR website:

Group	Dataset
Genitourinary	Carcinoma of the urethra - urethrectomy specimen
	Carcinoma of the renal pelvis and ureter - nephroureterectomy and ureterectomy specimen
	Urinary tract carcinoma - biopsy and transurethral resection specimen
	Carcinoma of the bladder - cystectomy, cystoprostatectomy and diverticulectomy specimen
	Invasive carcinoma of renal tubular origin
	Renal biopsy for tumour
	Carcinoma of the penis and distal urethra
	Neoplasia of the testis - retroperitoneal lymphadenectomy
	Neoplasia of the testis - orchidectomy specimen
	Prostate cancer - transurethral resection and enucleation specimen
	Prostate cancer - radical prostatectomy specimen

Group	Dataset
	Prostate - core needle biopsy
Digestive tract	Intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma
Thoracic	Lung cancer
	Thymic epithelial tumours
	Neoplasms of the heart, pericardium and great vessels
	Mesothelioma in the pleura and peritoneum
Gynaecology	Endometrial cancer
	Ovary, fallopian tube and primary peritoneal carcinoma
	Carcinoma of the cervix
Skin	Invasive melanoma

6.2 Breast Suite

Four datasets in the Breast Suite are being translated into the six priority languages (French (European), Spanish (European), Portuguese, German, Chinese and Russian) and two variants (French – Quebecois and Spanish – Latin American):

- Ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions
- Invasive carcinoma of the breast
- Invasive carcinoma of the breast in the setting of neoadjuvant therapy
- Surgically removed lymph nodes for breast tumours.

Translation is being done by IDEM, an ISO accredited translation company from Chicago. A quality assurance process is underway with the various Societies and Colleges of Pathology.

The project is funded through a very generously donation from the ASCP supplemented by donations from the International Society of Breast Pathology (ISBP) and the Singapore General Hospital Breast Pathology Course.

The purpose of the project is to enable the ICCR to explore the various issues and challenges involved in a project of this size which will inform future translation efforts.

6.3 Ukrainian

ICCR was approached in July 2022 by a group of Ukrainian pathologists wishing to translate several of the ICCR datasets into the Ukrainian language. As this was a single jurisdiction project not affecting a broader population, ICCR has agreed and is monitoring progress.

Ukrainian translation has been completed for the ICCR Colorectal cancer dataset.

6.4 Italian

ICCR has had discussions with SIAPEC and the Italian Ministry of Health regarding a project to translate ICCR datasets into Italian for national use, which is currently underway. ICCR and SIAPEC are in discussion regarding the progress of this project.

6.5 German

The German speaking members of the ICCR – Germany, Austria and Switzerland – have put forward a proposal to translate the ICCR datasets into German. Further discussion is planned between all parties, with an agreement pending.

6.6 Language specific webpages

Language specific pages have been added to the ICCR website to host the translated datasets. New pages will be added as needed in the future. An example is shown below:



6.6 Future translation

ICCR has 62 published datasets with many more being planned. It represents a large body of work to be translated and there is also the ongoing maintenance of the datasets to be considered. This requires a substantial investment in funding. ICCR will continue to investigate various options for funding as well as different models of translation.

7. IMPLEMENTATION

7.1 Structured Reporting Implementation Committee (SRIC)

ICCR convened the SRIC in 2021 for the purpose of providing guidance to the ICCR on matters relating to the implementation of ICCR Datasets and on the detailed technical aspects impacting the efficient implementation of standardised cancer datasets.

George Birdsong, Professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine, is the current Chair of the SRIC.

Membership of the committee includes those with expertise in electronic dataset development, terminology development, informatics and cancer reporting. The committee meet every 2-3 months.

7.2 Electronic ICCR datasets

To make best use of the ICCR datasets and eliminate the variability that is introduced when using a paper reference document, pathologists need access to structured reporting tools. Use of a reporting tool also facilitates electronic reporting to cancer registries, as well as improving workflow and supporting research through the availability of database searches etc.

In many parts of the world there are commercially available LIS or middleware solutions, which have the facility for structured data entry and storage to support the implementation of cancer datasets. Older LIS, which are currently incapable of electronic structured reporting, are gradually being replaced as they are upgraded, and as the importance of structured reporting of cancer is recognised.

However, in many LMICs there is little or no access to electronic structured reporting tools and reporting remains paper based, or at best done, on a standalone PC using word processing software.

ICCR needs a scalable solution that best serves the needs of locations with varying degrees of IT sophistication. A tiered approach is being discussed.

For mid-level sites, that is, those with reasonable IT capability, who have an existing LIS but lack adequate structured reporting tools, a solution providing user-friendly front-end reporting tools is needed. It is proposed that such an application would be electronically updateable and cater for multiple laboratory locations.

As noted above, there are laboratories with LIS or middleware solutions, with the facility for structured data entry. These would be classified as sites with a high level of IT capability. For these sites to implement ICCR datasets, they require uploadable files to ensure this is done quickly and efficiently.

Ideally the solution(s) chosen for the mid-level and high-level sites would be interoperable. The SRIC has completed a list of requirements to support this tiered approach within a Request for Proposal (RFP) document.

The SRIC committee has developed the RFP to include the necessary requirements for transposing the PDF ICCR datasets into electronic formats, to be sent to relevant vendors. A review of different technologies incorporated by the CAP and the Pathological Anatomical National Automated Archive of the Netherlands (PALGA) was incorporated in this evaluation.

7.3 Terminology

Coded terminology is very important to any pathology implementation as it reduces the variability of terms to a single unique code. Even common terms have variability e.g., lymphovascular space invasion, lymphovascular invasion, and lymph-vascular invasion. Different languages add another

layer of complexity. Coding of elements, for example lymphovascular invasion, and response values such as 'not identified' or 'present' with standard clinician terms like SNOMED CT reduces the variation and allows for advanced computer searches and interoperability.

Early in 2017, work commenced on the development of SNOMED CT content to represent the data elements in cancer datasets. This project is led by Scott Campbell from University of Nebraska Medical Centre, USA, under the auspices of the International Pathology and Laboratory Medicine Special Interest Group (IPaLM SIG) of the International Health Terminology Standards Development Organisation (IHTSDO), an international non-profit organisation that owns SNOMED CT. The encoding of cancer synoptic reports, including biomarkers, became an official project with SNOMED International later in 2017, ensuring both support and resources for content creation and publication.

The project aims to align terminology development and cancer dataset development efforts to truly create computable, interoperable cancer reporting tools for use by all participating nations.

8. FINANCES

8.1 Budget

The ICCR's financial year (FY) runs from 1 July to 30 June.

A budget based on expenses incurred in the previous year and what is anticipated to be needed in the current year was proposed and accepted at the August 2024 Council meeting for the financial year ending 30 June 2025.

8.2 Audited financial statement

The ICCR financial status is audited yearly by BDO Chartered Accountants. A fully audited financial statement was prepared and tabled at the AGM held on 21st November 2024.

In summary, assets exceed liabilities and with continuing support from the member organisations ICCR can meet its financial commitments now and in the foreseeable future.

BDO, in its report, did not raise any matters of concern.

8.3 Sustainability

While the membership and sponsorship provide funding for the continuation of ICCR's core business which is the development of cancer datasets, it does not allow for the necessary resources to push forward with translation, implementation, and education activities to the extent needed. The ICCR, therefore, has been investigating various potential fund-raising strategies with the kind assistance of Donna Meredith, Managing Director of Keystone Corporate Positioning, Australia.

The new ICCR website, logo and corporate profile will help position the ICCR to take advantage of new funding opportunities, especially in the philanthropic domain, in 2025.

8.4 Sponsorship

In addition to membership fees, the ICCR looks for sponsorship to help support the cost of development of datasets. The ICCR would like to express its gratitude to the following donors which provided donations in 2024:

- International Society of Urological Pathology
- Royal College of Pathologists of Australasia Quality Assurance Programs.

9 APPENDIX

9.1 Published datasets

The following is a list of ICCR published datasets as of November 2024:

Urinary/male genital

1. **Prostate cancer - radical prostatectomy specimen, 3rd edition**, which was developed for radical prostatectomy specimens for prostate carcinoma. Core biopsies and transurethral resection and enucleation specimens are dealt with in separate ICCR datasets. Rare urothelial carcinomas arising within the prostate are included in a separate ICCR dataset. Published: November 2024.
2. **Prostate cancer - transurethral resection and enucleation specimen, 2nd edition**, which was developed for the examination of transurethral resection or enucleation (suprapubic/simple/open prostatectomy or laser enucleation) specimens of the prostate. The dataset applies to invasive carcinomas of the prostate gland. Core biopsies and radical prostatectomy specimens are dealt with in separate ICCR datasets. Urothelial carcinomas arising in the bladder or urethra are dealt with in separate datasets. Rare urothelial carcinomas arising within the prostate are included in a separate dataset. Published: November 2024.
3. **Prostate - core needle biopsy, 2nd edition**, which was developed for the examination of prostate core needle biopsies. The dataset applies to invasive carcinomas of the prostate gland. Transurethral resection and enucleation specimens and radical prostatectomy specimens are dealt with in separate ICCR datasets. Urothelial carcinomas arising in the bladder or urethra are dealt with in separate datasets. Rare urothelial carcinomas arising within the prostate are included in a separate dataset. Published: November 2024.
4. **Invasive carcinoma of renal tubular origin, 1st edition**, which was developed for excision specimens of the kidney. Urothelial carcinoma arising from the upper renal tract, Wilms tumours and other nephroblastic and mesenchymal tumours are not included. This dataset is designed for the reporting of a single laterality of specimen i.e., left or right. Published: July 2017, Updated July 2018.
5. **Renal biopsy for tumour, 1st edition**, which was developed for core or wedge biopsy specimens for tumour of the kidney. Published: July 2017.
6. **Carcinoma of the penis and distal urethra, 2nd edition**, which was developed for the reporting of specimens from patients with carcinoma of the penis, including resection, biopsy, and lymphadenectomy. The protocol applies to primary carcinoma of the penis, as well as distal urethral squamous cell carcinomas (SCC) in males. SCCs of the fossa navicularis are reported using this dataset, while those arising from the proximal anterior urethra are reported using the ICCR Carcinomas of the urethra dataset. Melanomas and other urethral carcinomas are not included in the scope of this dataset – separate ICCR datasets are available and should be used for these neoplasms. Published: November 2024.
7. **Germ cell tumours of the testis – Orchidectomy, 2nd edition**, which was developed for the reporting of both partial and radical orchidectomy specimens from patients of any age with germ cell neoplasia of the testis. The dataset does not apply to sex cord-stromal tumours of the testis or to extra-gonadal germ cell tumours. The former have different criteria for malignancy from germ cell tumours, and the latter have an entirely separate staging system dependent on location. Sex cord stromal tumours are complex, with some types being entirely benign while others can be malignant. They are therefore too complex to include within this germ cell tumour focussed proforma. Paratesticular malignancies are also excluded for similar

reasons. This dataset does not include information on the excision of residual metastatic masses after chemotherapy. Published: November 2024.

8. **Neoplasia of the testis - retroperitoneal lymphadenectomy specimen, 2nd edition**, which was for the reporting of retroperitoneal and other lymphadenectomy specimens as well as visceral metastasis excision specimens from patients of any age with malignant tumours of the testis. The protocol applies to all malignant germ cell and sex cord-stromal tumours of the testis. Paratesticular malignancies are excluded. Published: November 2024.
9. **Carcinoma of the urethra - urethrectomy specimen, 1st edition**, which was developed for the reporting of resection specimens from patients with carcinoma of the urethra. The protocol applies to primary carcinomas (non-invasive and invasive), with or without associated epithelial lesions. Urothelial tumours diagnosed as papilloma or papillary urothelial neoplasm of low malignant potential are not carcinomas and this dataset does not apply to those diagnoses. Biopsy and transurethral resection specimens are dealt with in a separate dataset. Carcinomas arising in the distal penile urethra (glans region) are included in the Carcinoma of the penis and distal urethra dataset and are not to be reported using this dataset. This dataset is to be used for adenocarcinoma arising in the accessory glands of the urethra (Skene, Littre, Cowper). Published: May 2018.
10. **Carcinoma of the renal pelvis and ureter - nephroureterectomy and ureterectomy specimen, 1st edition**, which was developed for the reporting of resection specimens from patients with primary carcinoma of the ureter and renal pelvis. The protocol applies to carcinomas (non-invasive and invasive), with or without associated epithelial lesions. Urothelial tumours diagnosed as papilloma or papillary urothelial neoplasm of low malignant potential are not carcinomas and this dataset does not apply to those diagnoses. Biopsy and transurethral resection specimens are dealt with in a separate dataset. For bilateral tumours, complete a separate dataset for each. Published: May 2018.
11. **Carcinoma of the bladder - cystectomy, cystoprostatectomy and diverticulectomy specimen, 1st edition**, which was developed for the reporting of cystectomy, cystoprostatectomy or diverticulectomy specimens from patients with carcinoma of the bladder. The protocol applies to primary carcinomas (non-invasive and invasive), with or without associated epithelial lesions. Urothelial tumours diagnosed as papilloma or papillary urothelial neoplasm of low malignant potential are not carcinomas and this dataset does not apply to those diagnoses. Biopsy and transurethral resection specimens are dealt with in a separate dataset. Published: May 2018.
12. **Urinary tract carcinoma - biopsy and transurethral resection specimen, 1st edition**, which was developed for the reporting of biopsy and transurethral resection specimens of the bladder, urethra, ureter and renal pelvis. If biopsies are from different locations, then a separate dataset should be completed for each tumour site. The protocol applies to primary carcinomas (non-invasive and invasive), with or without associated epithelial lesions. Urothelial tumours diagnosed as papilloma or papillary urothelial neoplasm of low malignant potential are not carcinomas and this dataset does not apply to those diagnoses. The most distal portion of the penile urethra in the region of the glans penis is not included in this dataset; it is covered in the Carcinoma of the penis and distal urethra dataset. Published: May 2018.

Female reproductive organs

1. **Endometrial cancer, 5th edition**, which covers resection specimens of endometrial cancers, including carcinosarcomas. It is not applicable for small endometrial biopsy specimens. The 5th edition of this dataset incorporates the 2023 International Federation of Gynaecology and Obstetrics (FIGO) staging for endometrial carcinoma. Published: August 2024.

2. **Ovary, fallopian tube and primary peritoneal carcinoma, 2nd edition**, which was developed for resection specimens of primary borderline and malignant epithelial tumours of the ovary, fallopian tubes and peritoneum. It does not include non-epithelial ovarian neoplasms such as germ cell or sex cord stromal tumours or other primary peritoneal neoplasms such as mesothelioma. Published: September 2021.
3. **Carcinoma of the cervix, 5th edition**, which covers pathology reporting of primary cervical carcinomas. Specimens include loop/cone excisions, trachelectomies, simple and radical hysterectomies and exenterations. The dataset applies to epithelial neoplasms only and does not apply to small biopsy specimens. The 5th edition of this dataset incorporates the 2021 Union for International Cancer Control (UICC) Cervix Uteri TNM. Published: October 2023.
4. **Carcinoma of the vagina, 1st edition**, which was developed for the pathological reporting of resection specimens of primary carcinomas of the vagina (including carcinosarcomas). Haematopoietic neoplasms, mesenchymal neoplasms, mixed epithelial and mesenchymal neoplasms, malignant melanomas, other non-epithelial malignancies and metastatic tumours are excluded from this dataset. Due to the rarity of primary vaginal carcinomas, there is little published research regarding some of the elements included in this dataset and some of the parameters included are 'extrapolated' from primary cervical and vulval carcinomas and/or represent the opinions and experience of the members of the ICCR Carcinoma of the Vagina DAC. Published: August 2021.
5. **Carcinoma of the vulva, 2nd edition**, which was developed for the pathological reporting of resection specimens of primary carcinomas of the vulva. Haematopoietic neoplasms, mesenchymal neoplasms, mixed epithelial and mesenchymal neoplasms, malignant melanomas, other non-epithelial malignancies and metastatic tumours are excluded from this dataset. The 2nd edition of this dataset incorporates the 2021 International Federation of Gynaecology and Obstetrics (FIGO) staging for carcinoma of the vulva. Published: October 2023.
6. **Gestational trophoblastic neoplasia, 1st edition**, which was developed for the pathology reporting of resection specimens for primary uterine gestational trophoblastic neoplasia which includes invasive hydatidiform mole of either complete or partial type, gestational choriocarcinoma, placental site trophoblastic tumour and epithelioid trophoblastic tumour. The dataset should be used primarily for hysterectomy specimens. This dataset may also be used for rare myomectomy specimens but not all elements will be applicable. The dataset is not intended to be used for extrauterine primary lesions. Non-gestational trophoblastic tumours (germ cell or somatic origin) and metastatic tumours are excluded from this dataset. Published: August 2021.
7. **Uterine malignant and potentially malignant mesenchymal tumours, 1st edition**, which was developed for the pathology reporting of resection specimens of the uterus for sarcomas and mesenchymal tumours with potentially malignant behaviour. The dataset is applicable to tumours of the uterine corpus and the uterine cervix. Carcinomas, other non-mesenchymal malignancies and metastatic neoplasms are excluded from this dataset. Carcinosarcoma is also excluded as it is considered to represent a malignant epithelial tumour with divergent mesenchymal differentiation based on clinicopathologic, immunohistochemical and molecular analysis; as such, this entity is included in the ICCR Endometrial Cancer dataset. Published: August 2021.

Thorax

1. **Lung cancer, 4th edition**, which covers resection specimens of malignant epithelial cancers of the lung. The dataset applies to small cell carcinoma and carcinoid tumours, as well as non-small cell types of lung carcinoma. It is not applicable for bronchoscopic and transthoracic biopsy specimens. Published: April 2023.
2. **Mesothelioma in the pleura and peritoneum, 3rd edition**, which covers both biopsy and resection specimens of mesothelioma in the pleura, pericardium and peritoneum. Published: September 2022.
3. **Thymic epithelial tumours, 3rd edition**, which covers resection specimens of the thymus and is applicable for thymoma, neuroendocrine tumours of the thymus and thymic carcinoma. It does not apply to germ cell tumours, soft tissue tumours, haematolymphoid neoplasms, and other primary thymic neoplasms. Published: May 2022.
4. **Neoplasms of the heart, peritoneum and great vessels, 2nd edition**, which covers biopsy and resection specimens of neoplasms of the heart, pericardium, and great vessels. It includes both benign and malignant primary tumours of the heart, pericardium and great vessels. It does not apply to mesothelioma and haematolymphoid neoplasms. Published: December 2021.
5. **Tumours of the lung – small diagnostic and cytopathological specimens, 1st edition**, which covers small diagnostic biopsy specimens and cytopathological specimens of lung cancer. It can also be used for benign tumours or other non-neoplastic specimens at the discretion of the cytopathologist/pathologist. The dataset is also applicable to fine needle aspiration biopsy or core needle biopsy or excision specimens of metastatic lesions from a primary lung cancer. Published: December 2023.

Digestive tract

1. **Intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma, 2nd edition**, which covers resection specimens of the liver with intrahepatic, and perihilar cholangiocarcinoma and hepatocellular carcinoma. It does not apply to neuroendocrine carcinomas, hepatoblastoma, carcinomas of the extrahepatic bile ducts, gall bladder and benign lesions such as adenomas. Published: November 2020.
2. **Carcinoma of the exocrine pancreas, 1st edition**, which covers resection specimens with carcinomas of the exocrine pancreas, i.e., ductal adenocarcinoma and acinar cell carcinoma. It excludes carcinoma of the ampulla of Vater, common bile duct and duodenum, neuroendocrine neoplasia, lymphoma, sarcoma and secondary tumours. Published: April 2020.
3. **Colorectal cancer, 1st edition**, which covers surgical resection specimens from patients with primary carcinoma of the colon and rectum, including neuroendocrine carcinomas (NECs) and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs). It is not applicable to carcinomas of the small intestine, appendix or anus, nor to neuroendocrine tumours (NETs) or non-epithelial malignancies. Primary colorectal carcinomas treated by local excision are not included. Published: April 2020.
4. **Colorectal excisional biopsy (polypectomy) specimen, 1st edition**, which covers local excision specimens from the colon and rectum, including polypectomies, endoscopic mucosal resections (EMR), endoscopic submucosal dissections (ESD), endoscopic full thickness resections (EFTR), transanal submucosal excisions, transanal minimally invasive surgery (TAMIS) and transanal endoscopic microsurgery (TEMS) specimens. Surgical resection specimens from

patients with primary carcinoma of the colon and rectum, including NECs and MiNENs, are excluded. Published: April 2020.

5. **Carcinomas of the stomach, 2nd edition**, which covers gastrectomy for gastric carcinomas. Carcinomas involving the oesophagogastric junction (OGJ) with their epicentre >20 mm into the proximal stomach and cardia cancers that do not involve the OGJ are included. These criteria are set by the UICC/AJCC 8th edition Classifications and have been adopted by the WHO to define the diagnosis 'gastric cancer'. For all other tumours involving the OGJ, refer to the ICCR dataset for carcinomas of the oesophagus. NECs and MiNENs (with the exception of mixed adenoma and NETs) are included in this dataset. NETs, non-epithelial malignancies and secondary tumours are excluded from this dataset. Published: December 2021.
6. **Endoscopic resection of the stomach, 2nd edition**, which covers endoscopic resection (ER) specimens of the stomach. Surgically resected specimens are covered in a separate ICCR dataset. Carcinomas involving the oesophagogastric junction (OGJ) with their epicentre >20 mm into the proximal stomach and cardia cancers that do not involve the OGJ are included. These criteria are set by the UICC/AJCC on Cancer 8th edition TNM classifications and have been adopted by the WHO and define the diagnosis 'gastric cancer'. An ICCR dataset for carcinoma of the oesophagus is available for tumours not meeting these criteria. NECs and MiNENs (with the exception of mixed adenoma and NETs) are included in this dataset. NETs, non-epithelial malignancies, and secondary tumours are excluded from this dataset. Published: December 2021.
7. **Carcinomas of the oesophagus, 2nd edition**, which covers resection specimens of the oesophagus. Carcinomas involving the OGJ with tumour epicentre ≤20 mm into the proximal stomach are included. A separate ICCR dataset is available for endoscopic resections of the oesophagus and oesophagogastric junction. NEC and MiNEN of the oesophagus are included. NET, non-epithelial malignancies such as melanoma, and secondary tumours are excluded. Published: December 2021.
8. **Endoscopic resection of the oesophagus and oesophagogastric junction, 2nd edition**, which covers endoscopic resection (ER) of pre-malignant and malignant lesions of the oesophagus and OGJ. Surgically resected specimens are covered in a separate ICCR dataset. NEC and MiNEN of the oesophagus are included. NET, non-epithelial malignancies such as melanoma, and secondary tumours are excluded. Published: December 2021.

Skin

1. **Invasive melanoma, 2nd edition**, which was developed for reporting of primary cutaneous invasive melanoma. The 2nd edition of this dataset includes changes to align the dataset with the TNM Pathological staging 8th edition and the WHO Classification of Tumours, Pathology and Genetics of Skin Tumours (2018). Published: October 2019.
2. **Merkel cell carcinoma, 1st edition**, which covers primary cutaneous Merkel cell carcinoma (MCC) in excision (resection) specimens containing tumour. Published: December 2019.

Central nervous system

1. **Tumours of the central nervous system (CNS), 2nd edition**, which is split into three sections:
 - a. Histological assessment of CNS specimens. It is intended that this section should be used in conjunction with the other sections, where appropriate. A complete diagnosis of CNS tumours should ideally conform to the final integrated diagnoses in the 2021 WHO Classification of Tumours of the CNS, which for most tumour types now require

integration of elements from histological and ancillary analyses. Nonetheless, it is realised that some diagnoses may not fit precisely within existing diagnostic categories.

- b. Molecular information for CNS specimens. This section has been developed for the molecular assessment of primary CNS tumours, whether that molecular assessment is nucleic acid or protein-based. This section is to be used for those tumours in which molecular information is captured for diagnostic purposes.
- c. Final integrated report/diagnosis for CNS specimens. This dataset section should be used in conjunction with the sections on 'Histological assessment' and 'Molecular information', where appropriate.

Published: September 2024.

Head and neck

1. **Carcinomas of the nasal cavity and paranasal sinuses, 2nd edition**, which was developed for the reporting of resection and biopsy specimens of mucosal malignancies originating in the nasal cavities and paranasal sinuses. Malignancies at the border of skull base are included. Neuroendocrine neoplasms are also included. Bone, soft tissue and lymphoma protocols are separately listed. Neck dissections and nodal excisions are dealt with in a separate dataset, and this dataset should be used in conjunction, where applicable. Published: July 2024.
2. **Carcinomas of the hypopharynx, larynx and trachea, 2nd edition**, which was developed for the reporting of resection and biopsy specimens of invasive epithelial malignancies of the larynx, hypopharynx and trachea. Salivary-type malignancies arising from minor mucoserous glands of the hypopharynx and larynx should be recorded in this dataset. Mucosal melanoma is presented in a separate dataset. Lymphomas and sarcomas are not included. Malignancies arising at other sites in the head and neck region, and neck dissections and nodal excisions are dealt with in separate datasets which may be used, as appropriate, in conjunction with this dataset. Where more than one anatomically or histologically distinct primary tumours occur, a separate dataset should be completed for each tumour. Published: July 2024.
3. **Carcinomas of the oral cavity, 2nd edition**, which was developed for the reporting of resection and excisional biopsy specimens of malignancies of the oral cavity, including mucosal lip and tongue (mucosal carcinomas, minor salivary gland malignancies, and neuroendocrine tumours). Mucosal melanoma, lymphomas and sarcomas are dealt with in separate ICCR datasets. Published: July 2024.
4. **Carcinomas of the oropharynx and nasopharynx, 2nd edition**, which was developed for the reporting of resection and biopsy specimens of the oropharynx and nasopharynx. The protocol applies to all primary carcinomas (including of minor salivary glands) of the nasopharynx and oropharynx, the latter including the base of tongue, tonsils, tonsillar fossa, tonsillar pillars, soft palate, posterior and lateral walls, and uvula. Lymphomas and sarcomas are not included. Published: July 2024.
5. **Carcinomas of the major salivary glands, 2nd edition**, which was developed for the reporting of primary cancer resection and biopsy specimens of malignancies arising from the major salivary glands (parotid, submandibular and sublingual glands). For resections of recurrent disease, the reporting guide may be used pragmatically although some data elements may be not applicable nor assessable. Melanomas, lymphomas, and sarcomas are dealt with in separate datasets. Minor salivary gland malignancies arising in the oral cavity, nasal cavity and paranasal sinuses, larynx, hypopharynx, trachea, nasopharynx, oropharynx, gnathic

bones, and ear-temporal bone specimens are staged according to their anatomical sub-site and are dealt with in separate ICCR datasets. Published: July 2024.

6. **Malignant odontogenic tumours, 2nd edition**, which was developed for the reporting of excision biopsy and resection specimens for malignant primary odontogenic (carcinoma and sarcoma) tumours. Malignant neoplasms arising in the nasal cavity and paranasal sinuses, oral cavity, salivary glands, trachea, pharynx and larynx are dealt with in separate datasets. Non-odontogenic bone, soft tissue and lymphoma protocols are also dealt with in separate datasets. In addition, neck dissections and nodal excisions are dealt with in a separate dataset, and this dataset should be used in conjunction, where applicable. Published: July 2024.
7. **Ear and temporal bone tumours, 2nd edition**, which was developed for the reporting of resection and biopsy specimens of the ear and temporal bone. It includes only primary tumours of the external auditory canal, middle and inner ear, including both benign and malignant entities (specifically due to anatomic confines and management alternatives which may require significant, destructive or disfiguring surgery). By definition, all malignancies of the external ear (pinna, concha, scaphoid, lobe, etc., such as squamous cell carcinoma (SCC), basal cell carcinoma, pleomorphic dermal sarcoma, Merkel cell carcinoma and melanoma) are separately covered by the ICCR Skin Datasets. Published: July 2024.
8. **Mucosal melanomas of the head and neck, 2nd edition**, which was developed for the reporting of resection and biopsy specimens of mucosal melanoma arising in the nasopharynx, oropharynx, larynx, hypopharynx, oral cavity, nasal cavity and paranasal sinuses. All other malignancies and tumour categories are dealt with in separate datasets, specifically cutaneous melanoma is separately reported. Direct extension of a cutaneous primary into a mucosal site should be excluded and would not be reported in this dataset. Metastasis to a head and neck mucosal site is also excluded. Published: July 2024.
9. **Nodal excisions and neck dissection specimen, 2nd edition**, which was developed for the reporting of resection and biopsy specimens of mucosal melanoma arising in the nasal cavity and paranasal sinuses, oral cavity, nasopharynx, oropharynx, larynx and hypopharynx. All other malignancies are dealt with in separate ICCR datasets, specifically cutaneous melanoma is separately reported. Direct extension of a cutaneous primary into a mucosal site should be excluded and would not be reported in this dataset. Metastatic melanoma to a head and neck mucosal site is also excluded. Neck lymph node dissections and excisions are dealt with in a separate dataset, and this dataset should be used in conjunction, where applicable. Published: July 2024.

Endocrine

1. **Carcinoma of the adrenal cortex, 1st edition**, which covers malignant adrenal cortical resection specimens, borderline (low-malignant potential lesions), and paediatric adrenal cortical carcinomas. It excludes neuroblastoma, sarcoma, lymphoma, core needle biopsies, benign lesions and tumours and metastasis, and Tumours of the adrenal medulla (e.g., pheochromocytoma). Published: December 2019.
2. **Parathyroid carcinoma and atypical parathyroid neoplasm, 1st edition**, which covers parathyroid resection specimens when the diagnosis is atypical parathyroid neoplasm (atypical parathyroid adenoma or carcinoma. But excludes biopsies, sarcoma, lymphoma and metastasis. Published: December 2019.
3. **Pheochromocytoma and paraganglioma, 1st edition**, which covers adrenalectomy/ partial adrenalectomy specimens for pheochromocytoma, other excisions for paragangliomas and

biopsies of related specimens. It excludes sarcoma, lymphoma and metastasis to the adrenal medulla, neuroblastoma, ganglioneuroblastoma and adrenal cortical tumours. Published: December 2019.

4. **Carcinoma of the thyroid, 2nd edition**, which covers thyroid resection specimens for carcinoma, but excludes core needle biopsies and metastasis to the thyroid gland, invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), tumours of uncertain malignant potential (UMP), thyroid carcinomas arising from struma ovarii, thyroid carcinomas arising in thyroglossal duct cysts, sarcoma and lymphoma. Published: June 2020.

Soft tissue and bone

1. **Primary tumour in bone - biopsy specimens, 1st edition**, which was developed for the pathology reporting of biopsy specimens of primary tumour in bone. Ewing sarcoma and related round cell sarcomas with primary bone presentation are also covered by this dataset. A separate dataset is available for reporting of resection specimens of primary tumour in bone. Some types of soft tissue sarcoma may on rare occasion arise primarily in bone and should be reported using the primary tumour in bone dataset, rather than the soft tissue sarcoma dataset. If biopsies are taken from multiple tumour nodules at different sites, these should be documented separately. Haematologic malignancies and metastatic specimens are excluded from this dataset. Published: April 2021.
2. **Primary tumour in bone - resection specimens, 1st edition**, which was developed for the pathology reporting of resection specimens of primary tumour in bone. Ewing sarcoma and related round cell sarcomas with primary bone presentation are also covered in this dataset. A separate dataset is available for reporting biopsy specimens of primary tumour in bone. Some types of soft tissue sarcoma may on rare occasions arise primarily in bone and should be reported using the primary tumour in bone dataset, rather than the soft tissue sarcoma dataset. Haematologic malignancies and metastatic specimens are excluded from this dataset. Published: April 2021.
3. **Gastrointestinal stromal tumour (GIST) - biopsy specimens, 1st edition**, which was developed for the pathology reporting of biopsy specimens for GIST. Metastatic GIST specimens are excluded from this dataset. Published: April 2021.
4. **Gastrointestinal stromal tumour (GIST) - resection specimens, 1st edition**, which was developed for the pathology reporting of resection specimens for GIST. Metastatic GIST specimens are excluded from this dataset. Published: April 2021.
5. **Soft tissue sarcoma - biopsy specimens, 1st edition**, which was developed for the pathology reporting of biopsy specimens for soft tissue sarcomas. Adult rhabdomyosarcoma is also included in this dataset. A separate ICCR dataset is available for reporting of resection specimens for soft tissue sarcomas. Some soft tissue tumours which rarely arise primarily in bone should be reported using the ICCR primary tumour in bone datasets. Lymphoma, uterine sarcoma, paediatric rhabdomyosarcoma and metastases are excluded from this dataset. GIST are also not included in this dataset as GIST displays a number of unique features which warrant its separate consideration; separate ICCR datasets for GIST are available. Published: April 2021.
6. **Soft tissue sarcoma - resection specimens, 1st edition**, which was developed for the pathology reporting of resection specimens for soft tissue sarcomas. Adult rhabdomyosarcoma is also included in this dataset. A separate ICCR dataset is available for reporting of biopsy specimens for soft tissue sarcomas. Some soft tissue tumours which rarely arise primarily in bone and in this case should be reported using the ICCR primary tumour in bone datasets. Lymphoma, uterine

sarcoma, paediatric rhabdomyosarcoma and metastases are excluded from this dataset. GIST are also not included in this dataset as GIST displays a number of unique features which warrant its separate consideration; separate ICCR datasets for GIST are available. Published: April 2021.

Breast

1. **Ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions, 1st edition**, which was developed for the reporting of resection specimens for ductal carcinoma in situ (DCIS) of the breast. The protocol applies to cases of DCIS and for where microinvasion (≤ 1 mm) is present. It also covers other in situ lesions including pleomorphic and florid variants of lobular carcinoma in situ (LCIS), as well as encapsulated papillary carcinoma and solid papillary carcinoma in situ. This dataset may also be used in those rare cases of DCIS removed at core biopsy but without evidence of residual DCIS in a subsequent excision specimen. This protocol should only be used for re-excisions when they contain the largest extent of DCIS. A separate dataset should be completed for bilateral DCIS and for each excision specimen in unilateral disease. DCIS (with or without microinvasion) diagnosed on needle core biopsies only, and residual DCIS post neoadjuvant therapy are outside the scope. Separate ICCR datasets cover DCIS associated with invasive breast carcinomas and breast resections in the neoadjuvant setting. Surgically removed lymph nodes are covered in a separate ICCR dataset which may be used, as appropriate, in conjunction with this dataset. Published: June 2021.
2. **Invasive carcinoma of the breast, 2nd edition**, which was developed for the reporting of resection specimens from patients with invasive carcinoma of the breast, with or without DCIS. DCIS without invasive carcinoma and microinvasive carcinoma (≤ 1 mm) are dealt with in a separate ICCR dataset. Ipsilateral multifocal disease should be dealt with in a single report. For bilateral invasive breast tumours, a separate dataset should be completed for each side. Surgically removed lymph nodes are dealt with in a separate ICCR dataset which may be used, as appropriate, in conjunction with this dataset. Invasive breast cancer for the post neoadjuvant setting is also dealt with in a separate ICCR dataset. Published: June 2022.
3. **Invasive carcinoma of the breast in the setting of neoadjuvant therapy, 2nd edition**, which was developed for the reporting of resection specimens after neoadjuvant therapy from patients with invasive carcinoma of the breast with or without DCIS. This dataset is for post-treatment surgical specimens. Core needle biopsies are not included. Published: May 2023.
4. **Surgically removed lymph nodes for breast tumours, 1st edition**, which was developed for the reporting of surgically removed ipsilateral lymph nodes (including lymph node dissection, targeted axillary surgery, nodal sampling and sentinel node biopsy specimens) for breast tumours. It is not intended for use in reporting core biopsy or fine needle aspiration of lymph nodes. The assessment of ipsilateral lymph nodes is part of nodal staging of breast cancer, whereas the rare contralateral lymph node involvement is currently interpreted as distant metastasis and is not part of the dataset. The reporting of invasive breast cancer and in situ disease (DCIS, pleomorphic and florid LCIS, encapsulated papillary carcinoma and solid papillary carcinoma in situ) are dealt with in separate ICCR datasets which may be used, as appropriate, in conjunction with this dataset. Published: May 2021.

Paediatrics

1. **Paediatric renal tumours, 1st edition**, was developed for the examination of resection specimens from paediatric patients with nephroblastoma also known as Wilms tumour, and all other renal tumours of childhood except renal cell carcinomas. It does not apply to procedures involving only biopsy. Published: November 2023.

2. **Paediatric rhabdomyosarcoma, 1st edition**, was developed for the pathological reporting of biopsy and resection specimens of paediatric rhabdomyosarcoma. The dataset covers both pre- and post-treatment specimens. Published: November 2023.
3. **Neuroblastoma, 1st edition**, was developed for the pathological reporting of biopsy and resection specimens of paediatric peripheral neuroblastic tumours. Published: November 2023.
4. **Hepatoblastoma, 1st edition**, was developed for the pathological reporting of resection specimens of paediatric hepatoblastoma, including tumours in the hepatocellular neoplasm not otherwise specified category. It is not applicable to hepatocellular carcinomas nor to other primary or metastatic paediatric neoplasms of the liver. Published: November 2023.

9.2 Peer-reviewed publications

- Dataset for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR). Cooper WA, Webster F, Butnor KJ, Calabrese F, Chou T, Hwang DM, Kern I, Popat S, Sholl L, Yatabe Y, Nicholson AG. *Histopathology*. 2024 Oct 22. doi: 10.1111/his.15313. Epub ahead of print.
- Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR). Ellis I, Webster F, Allison KH, Dang C, Gobbi H, Kulka J, Lakhani SR, Moriya T, Quinn CM, Sapino A, Schnitt S, Sibbering DM, Slodkowska E, Yang W, Tan PH. *Histopathology*. 2024 Sep;85(3):418-436. doi: 10.1111/his.15191. Epub 2024 May 8.
- A dedicated structured dataset for reporting of Invasive Carcinoma of the Breast in the Setting of Neoadjuvant Therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR). Bossuyt V, Provenzano E, Symmans WF, Webster F, Allison KH, Dang C, Gobbi H, Kulka J, Lakhani SR, Moriya T, Quinn CM, Sapino A, Schnitt S, Sibbering DM, Slodkowska E, Yang W, Tan PH, Ellis I. *Histopathology*. 2024 Mar 5. doi: 10.1111/his.15165. Epub ahead of print.
- Invasive breast cancer reporting guidelines: ICCR, CAP, RCPATH, RCPA datasets and future directions. Laokulrath N, Gudi MA, Deb R, Ellis IO, Tan PH. *Diagnostic Histopathology*. Volume 30, Issue 2, Feb 2024, Pages 87-99. doi.org/10.1016/j.jmpdhp.2023.11.001.
- Mesothelioma in the pleura, pericardium and peritoneum: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Klebe S, Judge M, Brcic L, Dacic S, Galateau-Salle F, Nicholson AG, Roggli V, Nowak AK, Cooper WA. *Histopathology*. 2023 Dec 4. doi: 10.1111/his.15106. Epub ahead of print.
- Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Roden AC, Judge M, den Bakker MA, Fang W, Jain D, Marx A, Moreira AL, Rajan A, Stroebel P, Szolkowska M, Cooper WA. *Histopathology*. 2023 Sep 18. doi: 10.1111/his.15047. Epub ahead of print.
- An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative. Ellis IO, Rakha EA, Tse GM, Tan PH. *Histopathology*. 2023 Jan;82(1):189-197. doi: 10.1111/his.14802.
- Datasets for reporting of soft-tissue sarcoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Dei Tos AP, Webster F, Agaimy A, Bovée J, Dickson B, Doyle L, Dry S, Gronchi A, Hameed M, Hemmings C, Liegl-Atzwanger B, Thway K, Wagner AJ, Wang J, Yoshida A, Fletcher C. *Histopathology*. 2023 Apr;82(5):745-754. Doi: 10.1111/his.14862. Epub 2023 Jan 20.

- Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR). Bovée JVMG, Amary F, Baumhoer D, Bloem JL, Bridge JA, Cates JMM, de Alava E, Dei Tos AP, Jones KB, Mahar A, Nielsen GP, Righi A, Wagner AJ, Yoshida A, Fletcher CDM. *Histopathology*. 2023 Mar;82(4):531-540. doi: 10.1111/his.14849. Epub 2022 Dec 20.
- Dataset for the reporting of neoplasms of the heart, pericardium, and great vessels: recommendations from the International Collaboration on Cancer Reporting (ICCR). Maleszewski JJ, Basso C, Burke A, Castonguay M, Leduc C, Tavora F, Sheppard M, Suri R, Judge M, Cooper WA. *Virchows Arch*. 2023 Feb;482(2):303-309. doi: 10.1007/s00428-022-03473-7. Epub 2022 Dec 13.
- Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting. Cserni G, Brogi E, Cody HS, Deb R, Farshid G, O'Toole S, Provenzano E, Quinn CM, Sahin AA, Schmitt F, Weaver DL, Yamaguchi R, Webster F, Tan PH. *Arch Pathol Lab Med*. 2022 Nov 1;146(11):1308-1318. doi: 10.5858/arpa.2022-0060-RA.
- International Collaboration on Cancer Reporting (ICCR) Gynecological Cancer Datasets: A Move Towards International Standardization. McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S1-S2. doi: 10.1097/PGP.0000000000000872. Epub 2022 Oct 24.
- The International Collaboration on Cancer Reporting (ICCR): 10 Years Progress in the Development of Cancer Pathology Datasets. Helliwell TR, Judge MJ, Birdsong GG, Ellis DW, Strigley JR. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S3-S7. doi: 10.1097/PGP.0000000000000899. Epub 2022 Aug 11.
- Data Set for the Reporting of Carcinomas of the Vulva: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Hoang L, Webster F, Bosse T, Focchi G, Gilks CB, Howitt BE, McAlpine JN, Ordi J, Singh N, Wong RW, Lax SF, McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S8-S22. doi: 10.1097/PGP.0000000000000900. Epub 2022 Oct 10.
- Data Set for the Reporting of Carcinomas of the Vagina: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Wong RW, Webster F, Bosse T, Focchi G, Gilks CB, Hoang L, Howitt BE, McAlpine J, Ordi J, Singh N, Lax SF, McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S23-S33. doi: 10.1097/PGP.0000000000000883. Epub 2022 May 20.
- Data Set for Reporting of Uterine Malignant and Potentially Malignant Mesenchymal Tumors: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Nucci MR, Webster F, Croce S, George S, Howitt BE, Ip PPC, Lee CH, Rabban JT, Soslow RA, van der Griend R, Lax SF, McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S44-S63. doi: 10.1097/PGP.0000000000000911. Epub 2022 Sep 22.
- Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Busam KJ, Judge MJ, Bichakjian CK, Coit D, Kutzner H, Requena L, Scolyer RA, Stefanato CM, Wood BA, Walsh NM. *Am J Surg Pathol*. 2022 Nov 1;46(11):1583-1591. doi: 10.1097/PAS.0000000000001959. Epub 2022 Aug 25.
- Dataset for the Reporting of Gestational Trophoblastic Neoplasia: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Hui P, Webster F, Baergen RN, Buza N, Cheung ANY, Kaur B, Ronnett BM, Shih IM, Seckl MJ, Lax SF, McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S34-S43. doi: 10.1097/PGP.0000000000000876. Epub 2022 Oct 24.

- Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Gilks CB, Selinger CI, Davidson B, Köbel M, Ledermann JA, Lim D, Malpica A, Mikami Y, Singh N, Srinivasan R, Vang R, Lax SF, McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S119-S142. doi: 10.1097/PGP.0000000000000908. Epub 2022 Oct 24.
- Data Set for the Reporting of Endometrial Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Matias-Guiu X, Selinger CI, Anderson L, Buza N, Ellenson LH, Fadare O, Ganesan R, Ip PPC, Palacios J, Parra-Herran C, Raspollini MR, Soslow RA, Werner HMJ, Lax SF, McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S90-S118. doi: 10.1097/PGP.0000000000000901. Epub 2022 Oct 24.
- Dataset for the Reporting of Carcinoma of the Cervix: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Park KJ, Selinger CI, Alvarado-Cabrero I, Duggan MA, Kiyokawa T, Mills AM, Ordi J, Otis CN, Plante M, Stolnicu S, Talia KL, Wiredu EK, Lax SF, McCluggage WG. *Int J Gynecol Pathol*. 2022 Nov 1;41(Suppl 1):S64-S89. doi: 10.1097/PGP.0000000000000909. Epub 2022 Aug 19.
- Pathology Reporting of Gastric Endoscopic Resections: Recommendations from the International Collaboration on Cancer Reporting. Shi C, Webster F, Nagtegaal ID, Dataset Authoring Committee for the development of the ICCR Dataset for Pathology Reporting of Gastric Endoscopic Resections. *Gastroenterology*. 2021 Nov 11:S0016-5085(21)03733-1. doi: 10.1053/j.gastro.2021.11.010. *Gastroenterology*. 2023 Jun;164(7):1039-1043. doi: 10.1053/j.gastro.2021.11.010. Epub 2022.
- Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR). Fox SB, Webster F, Chen CJ, Chua B, Collins L, Foschini MP, Bruce Mann G, Millar E, Pinder SE, Rakha E, Shaaban A, Tan BY, Tse G, Watson P, Tan PH. *Histopathology*. 2022 Oct;81(4):467-476. doi: 10.1111/his.14725. Epub 2022 Aug 8.
- Data Set for Reporting Carcinoma of the Stomach in Gastrectomy: Recommendations from the International Collaboration on Cancer Reporting. Shi C, Badgwell BD, Grabsch HI, Gibson MK, Hong SM, Kumarasinghe P, Lam AK, Lauwers G, O'Donovan M, van der Post RS, Tang L, Ushiku T, Vieth M, Selinger CI, Webster F, Nagtegaal ID. *Arch Pathol Lab Med*. 2022 Sep 1;146(9):1072-1083. doi: 10.5858/arpa.2021-0225-OA.
- Dataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Hornick JL, Webster F, Dei Tos AP, Hemmings C, Miettinen M, Oda Y, Raut CP, Rubin BP, Von Mehren M, Wardelmann E, Fletcher CDM. *Histopathology*. 2023 Feb;82(3):376-384. doi: 10.1111/his.14791. Epub 2022 Sep 20.
- Dataset for Pathology Reporting of Colorectal Cancer: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Loughrey MB, Webster F, Arends MJ, Brown I, Burgart LJ, Cunningham C, Flejou JF, Kakar S, Kirsch R, Kojima M, Lugli A, Rosty C, Sheahan K, West NP, Wilson RH, Nagtegaal ID. *Ann Surg*. 2022 Mar 1;275(3):e549-e561. doi: 10.1097/SLA.0000000000005051.
- Pathology Reporting of Esophagus Endoscopic Resections: Recommendations from the International Collaboration on Cancer Reporting. Lam AK, Nagtegaal ID, Dataset Authoring Committee for the development of the ICCR Dataset for Endoscopic Resection of the Esophagus and Esophagogastric Junction. *Gastroenterology*. 2022 Feb;162(2):373-378. doi: 10.1053/j.gastro.2021.09.069. Epub 2021 Oct 14.

- Dataset for the reporting of carcinoma of the exocrine pancreas: recommendations from the International Collaboration on Cancer Reporting (ICCR). Verbeke C, Webster F, Brosens L, Campbell F, Del Chiaro M, Esposito I, Feakins RM, Fukushima N, Gill AJ, Kakar S, Kench JG, Krasinskas AM, van Laethem JL, Schaeffer DF, Washington K. *Histopathology*. 2021 Dec;79(6):902-912. doi: 10.1111/his.14540. Epub 2021 Sep 22.
- Pathology Reporting of Colorectal Local Excision Specimens: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Rosty C, Webster F, Nagtegaal ID; Dataset Authoring Committee for the development of the ICCR Dataset for Pathology Reporting of Colorectal Excisional Biopsy. *Gastroenterology*. 2021 Aug;161(2):382-387. doi: 10.1053/j.gastro.2021.04.066. Epub 2021 May 4.
- Dataset for the reporting of carcinoma of the oesophagus in resection specimens: recommendations from the International Collaboration on Cancer Reporting. Lam AK, Bourke MJ, Chen R, Fiocca R, Fujishima F, Fujii S, Jansen M, Kumarasinghe P, Langer R, Law S, Meijer SL, Muldoon C, Novelli M, Shi C, Tang L, Nagtegaal ID. *Hum Pathol*. 2021 Aug;114:54-65. doi: 10.1016/j.humpath.2021.05.003. Epub 2021 May 13.
- Pathology Reporting of Colorectal Local Excision Specimens: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Rosty C, Webster F, Nagtegaal ID; Dataset Authoring Committee for the development of the ICCR Dataset for Pathology Reporting of Colorectal Excisional Biopsy. *Gastroenterology*. 2021 Aug;161(2):382-387. doi: 10.1053/j.gastro.2021.04.066. Epub 2021 May 4.
- Dataset for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Giordano TJ, Berney D, de Krijger RR, Erickson L, Fassnacht M, Mete O, Papathomas T, Papotti M, Sasano H, Thompson LDR, Volante M, Gill AJ. *Hum Pathol*. 2021 Apr;110:50-61. doi: 10.1016/j.humpath.2020.10.001. Epub 2020 Oct 12.
- Dataset for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. Ghossein R, Barletta JA, Bullock M, Johnson SJ, Kakudo K, Lam AK, Moonim MT, Poller DN, Tallini G, Tuttle RM, Xu B, Gill AJ. *Hum Pathol*. 2021 Apr;110:62-72. doi: 10.1016/j.humpath.2020.08.009. Epub 2020 Sep 10.
- Pathology data set for reporting parathyroid carcinoma and atypical parathyroid neoplasm: recommendations from the International Collaboration on Cancer Reporting. Williams MD, DeLellis RA, Erickson LA, Gupta R, Johnson SJ, Kameyama K, Natsu S, Ng T, Perren A, Perrier ND, Seethala RR, Gill AJ. *Hum Pathol*. 2021 Apr;110:73-82. doi: 10.1016/j.humpath.2020.07.008. Epub 2020 Jul 17.
- Dataset for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Thompson LDR, Gill AJ, Asa SL, Clifton-Bligh RJ, de Krijger RR, Kimura N, Komminoth P, Lack EE, Lenders JWM, Lloyd RV, Papathomas TG, Sadow PM, Tischler AS. *Hum Pathol*. 2021 Apr;110:83-97. doi: 10.1016/j.humpath.2020.04.012. Epub 2020 May 11.
- Dataset for the reporting of carcinoma of the bladder – cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Comp  rat E, Srigley JR, Brimo F, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samarasinghe H, Shanks JH, Suzuki T, van der Kwast T, Varma M, Webster F, Grignon D. *Virchows Arch*. 2020 Apr;476(4):521-534. doi: 10.1007/s00428-019-02727-1. Epub 2020 Jan 8.

- Dataset for the reporting of urinary tract carcinoma – biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). Varma M, Srigley JR, Brimo F, Comp  rat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Shanks JH, Tsuzuki T, van der Kwast T, Webster F, Grignon D. *Mod Pathol*. 2020 Apr;33(4):700–712. doi: 10.1038/s41379-019-0403-9. Epub 2019 Nov 4.
- Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Shanks JH, Srigley JR, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, Reuter V, Samaratunga H, Tsuzuki T, van der Kwast T, Varma M, Grignon D. *Histopathology*. 2019 Oct;75(4):453–467. doi: 10.1111/his.13877. Epub 2019 Jul 2.
- Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter–Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Samaratunga H, Judge M, Delahunt B, Srigley J, Brimo F, Comperat E, Koch M, Lopez-Beltran A, Reuter V, Shanks J, Tsuzuki T, van der Kwast T, Varma M, Grignon D. *Am J Surg Pathol*. 2019 Oct;43(10):e1–e12. doi: 10.1097/PAS.0000000000001305.
- Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. Kench JG, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J6, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Egevad L, Virchow Arch. 2019 Sep;475(3):263–277. doi: 10.1007/s00428-019-02574-0. Epub 2019 May 16.
- Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). Delahunt B, Srigley JR, Judge M, Amin M, Billis A, Camparo P, Fleming S, Griffiths D, Lopez-Beltran A, Martignoni G, Moch H, Nacey JN, Zhou M, Evans AJ. *J Clin Pathol*. 2019 Sep;72(9):573–578. doi: 10.1136/jclinpath-2019-205959. Epub 2019 Jul 12.
- Datasets for the Reporting of Tumors of the Central Nervous System. Louis DN, Wesseling P, Brandner S, Brat DJ, Ellison DW, Giangaspero F, Hattab EM, Hawkins C, Judge MJ, Kleinschmidt-DeMasters B, Komori T, McLean C, Paulus W, Perry A, Reifenberger G, Weller M, Rous B. *Arch Pathol Lab Med*. 2020 Feb;144(2):196–206. doi: 10.5858/arpa.2018-0565-OA. Epub 2019 Jun 20.
- Dataset for the reporting of carcinomas of the major salivary glands: Explanations and recommendations of the guidelines from the international collaboration on cancer reporting (ICCR). Seethala RR, Altemani A, Ferris RL, Fonseca I, Gnepp DR, Ha P, Nagao T, Skalova A, Stenman G, Thompson LDR. *Arch Pathol Lab Med*. 2019 May;143(5):578–586. doi: 10.5858/arpa.2018-0422-SA. Epub 2018 Nov 30.
- Dataset for the reporting of malignant odontogenic tumors: Explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Slootweg PJ, Odell EW, Baumhoer D, Carlos R, Hunter KD, Taylor AM, Richardson MS, Slater L, Speight PM, Wright J, Thompson LDR. *Arch Pathol Lab Med*. 2019 May;143(5):587–592. doi: 10.5858/arpa.2018-0417-SA. Epub 2018 Nov 30.
- Data Set for the Reporting of Mucosal Melanomas of the Head and Neck: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting. Williams MD, Franchi A, Helliwell T, M  ller S, Thompson LDR. *Arch Pathol Lab Med*. 2019 May;143(5):603–609. doi: 10.5858/arpa.2018-0412-SA. Epub 2018 Nov 30.

- Dataset for the reporting of ear and temporal bone tumours: Explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Gupta R, Sandison A, Wenig BM, Thompson LDR. Arch Pathol Lab Med. 2019 May;143(5):593–602. doi: 10.5858/arpa.2018–0415–SA. Epub 2018 Nov 30.
- Dataset for the reporting of carcinomas of the nasal cavity and paranasal sinuses: Explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Franchi A, Bishop JA, Coleman H, Flucke U, Licitra LF, Pendás JLL, Stelow EB, Toner M, Weinreb I, Wenig BM, Thompson LDR. Arch Pathol Lab Med. 2019 Apr;143(4):424–431. doi: 10.5858/arpa.2018–0404–SA. Epub 2018 Nov 30.
- Dataset for the reporting of oral cavity carcinomas: Explanations and recommendations of the guidelines from the International Collaboration of Cancer Reporting. Müller S, Boy SC, Day TA, Magliocca KR, Richardson MS, Sloan P, Tilakaratne WM, Zain RB, Thompson LDR. Arch Pathol Lab Med. 2019 Apr;143(4):439–446. doi: 10.5858/arpa.2018–0411–SA. Epub 2018 Nov 30.
- Dataset for the reporting of carcinomas of the nasopharynx and oropharynx: Explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting (ICCR). Lewis JS Jr, Adelstein DJ, Agaimy A, Carlson D, Faquin WC, Helliwell T, Hille J, Ng T, Nicholls J, O'Sullivan B, Thompson LDR. Arch Pathol Lab Med. 2019 Apr;143(4):447–451. doi: 10.5858/arpa.2018–0405–SA. Epub 2018 Nov 30.
- Dataset for the reporting of nodal excisions and neck dissection specimens for head and neck tumors: Explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Bullock M, Beitler J, Carlson DL, Fonseca I, Hunt J, Katabi N, Sloan P, Taylor SM, Williams M, Thompson LDR. Arch Pathol Lab Med. 2019 Apr;143(4):452–462. doi: 10.5858/arpa.2018–0421–SA. Epub 2018 Nov 30.
- Dataset for reporting of carcinomas of the hypopharynx, larynx and trachea: Explanations and recommendations of the Guidelines from the International Collaboration on Cancer Reporting. Helliwell T, Chernock R, Dahlstrom J, Gale N, McHugh J, Perez–Ordóñez B, Roland N, Zidar N, Thompson LDR. Arch Pathol Lab Med. 2019 Apr;143(4):432–438. doi: 10.5858/arpa.2018–0419–SA. Epub 2018 Nov 30.
- Dataset for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). Delahunt B, Srigley JR, Judge MJ, Amin MB, Billis A, Camparo P, Evans AJ, Fleming S, Griffiths D, Lopez–Beltran A, Martignoni G, Moch H, Nacey JN, Zhou M. Histopathology. 2019 Feb;74(3):377–390. doi: 10.1111/his.13754.
- Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Berney DM, Comperat E, Feldman DR, Hamilton RJ, Idrees MT, Samarasinghe H, Tickoo SK, Yilmaz A, Srigley JR. Histopathology. 2019 Jan;74(1):171–183. doi: 10.1111/his.13736.
- Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Egevad L, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Kench JG. Pathology. 2019 Jan;51(1):11–20. doi: 10.1016/j.pathol.2018.10.003. Epub 2018 Nov 23.

- Dataset for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW. *Histopathology*. 2018 Sep;73(3):369–385. doi: 10.1111/his.13520. Epub 2018 May 30.
- Dataset for the Reporting of Carcinomas of the Cervix: Recommendations from the International Collaboration on Cancer Reporting (ICCR). McCluggage WG, Judge MJ, Alvarado-Cabrero I, Duggan MA, Horn LC, Hui P, Ordi J, Otis CN, Park KJ, Plante M, Stewart CJR, Wiredu EK, Rous B, Hirschowitz L. *Int J Gynecol Pathol*. 2018 May;37(3):205–228. doi: 10.1097/PGP.0000000000000412.
- Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR). Nicholson AG, Detterbeck F, Marx A, Roden AC, Marchevsky AM, Mukai K, Chen G, Marino M, den Bakker MA, Yang WJ, Judge M, Hirschowitz L. *Histopathology*. 2017 Mar;70(4):522–538. doi: 10.1111/his.13099. Epub 2016 Nov 28.
- Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Churg A, Attanoos R, Borczuk AC, Chirieac LR, Galateau-Salle F, Gibbs A, Henderson D, Roggli V, Rusch V, Judge MJ and Srigley JR. *Arch Pathol Lab Med*. 2016 Oct;140(10):1104–10. doi: 10.5858/arpa.2016-0073-OA. Epub 2016 Mar 31.
- Dataset for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). McCluggage WG, Judge MJ, Clarke BA, Davidson B, Gilks CB, Hollema H, Ledermann J, Matias-Guiu X, Mikami Y, Stewart CJR, Vang R and Hirschowitz L. *Mod Pathol*. 2015 Aug;28(8):1101–22. doi: 10.1038/modpathol.2015.77. Epub 2015 Jun 19.
- Dataset for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Scolyer RA, Judge MJ, Evans A, Frisberg DP, Prieto VG, Thompson JF, Trotter MJ, Walsh MY, Walsh NM, Ellis DW. *Am J Surg Pathol*. 2013 Dec;37(12):1797–814. doi: 10.1097/PAS.0b013e31829d7f35.
- Dataset for reporting of lung carcinomas: recommendations from International Collaboration on Cancer Reporting. Jones KD, Churg A, Henderson DW, Hwang DM, Ma Wyatt J, Nicholson AG, Rice AJ, Washington MK, Butnor KJ. *Arch Pathol Lab Med*. 2013 Aug;137(8):1054–62. doi: 10.5858/arpa.2012-0511-OA.
- Dataset for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. McCluggage WG, Colgan T, Duggan M, Hacker NF, Mulvany N, Otis C, Wilkinson N, Zaino RJ and Hirschowitz L. *Int J Gynecol Pathol*. 2013 Jan;32(1):45–65. doi: 10.1097/PGP.0b013e31825d808b.
- Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Kench J, Delahunt B, Griffiths DF, Humphrey PA, McGowan T, Trpkov K, Varma M, Wheeler TM and Srigley JR. *Histopathology*. 2013 Jan;62(2):203–18. doi: 10.1111/his.12042.